Frontlight ResearchEarly access
TerminatedPhase 2/3
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Key facts
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2/3
- People taking part
- 62 people enrolled
- Started
- 22 Jun 2021
- Ended
- 17 Apr 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SHR-1701、 BP102 、XELOX
- placebo、 BP102、 XELOX
- Record updated
- 18 May 2025
- Why it stopped
- Adjustment of the Company's R\&D Strategy
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients with unresectable recurrent or metastatic adenocarcinoma of the colon or rectum confirmed histologically
- For subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
- At least 1 measurable lesion according to RECIST V1.1
- The vital organs are functioning well
- ECOG score is 0 ~ 1
- Contraception was initiated from the signing of the informed consent until at least 6 months after the last dosing of the study drug
Who cannot take part
- Recurrent or metastatic lesions can be treated with radical surgery
- Poorly controlled hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in the case of regular antihypertensive therapy) and prior hypertensive crisis or hypertensive encephalopathy
- Subject with current interstitial pneumonia or interstitial lung disease, or with a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy
- Previous treatment with targeted T cell costimulatory molecules and immune checkpoint inhibitors;Previous treatment with antiepidermal growth factor receptor or any antiangiogenic drug
- Severe cardiovascular and cerebrovascular diseases;Have clinical heart symptoms or diseases that are not well controlledSubjects with a history of myocardial infarction or unstable angina pectoris
- Presence of central nervous system or meningeal metastases
- Moderate and severe ascites of clinical symptoms;Uncontrolled or moderate or greater pleural effusion or pericardial effusion
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.
The 3 groups in the trial
- SHR-1701 in combination with BP102 and XELOX(Phase 2)Treatment being tested
Treatment: SHR-1701、 BP102 、XELOX
- SHR-1701 in combination with BP102 and XELOX (Phase 3)Treatment being tested
Treatment: SHR-1701、 BP102 、XELOX
- placebo in combination with BP102 and XELOXPlacebo, for comparison
Treatment: placebo、 BP102、 XELOX
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Study of SHR-1701 or Placebo in Combination With BP102 (Biosimilar to Bevacizumab) and XELOX in First-line Treatment of mCRC
- Publications
- Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.Signal transduction and targeted therapy, 2024
- Record updated
- 18 May 2025